CARISMA Therapeutics Q4 EPS $(0.52) Beats $(0.55) Estimate, Sales $4.29M Beat $2.90M Estimate
Portfolio Pulse from Benzinga Newsdesk
CARISMA Therapeutics (NASDAQ:CARM) reported Q4 earnings with losses of $(0.52) per share, surpassing the $(0.55) estimate. Quarterly sales reached $4.29M, exceeding the $2.90M estimate.

April 01, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CARISMA Therapeutics reported better-than-expected Q4 earnings and sales, with losses per share of $(0.52) and sales of $4.29M.
Beating both earnings and sales estimates typically generates positive investor sentiment, potentially leading to a short-term increase in stock price. The significant beat on sales estimates by nearly 48% is particularly noteworthy, indicating stronger than expected revenue generation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100